Isoniazid is the drug of choice for the treatment of latent TB infections (LTBI) and a cornerstone in active infections. [4,7,28,30] It is a powerful mycobactericidal agent that is effective in early ...

There were an estimated 490,000 new cases of drug-resistant TB in 2016. Tuberculosis, a lung disease most often transmitted by breathing infected particles in the air, is the ninth leading cause of ...

We enrolled 41 patients who had sputum-culture–positive extensively drug-resistant (XDR) tuberculosis and who had not had a response to any available chemotherapeutic option during the previous 6 ...

Cases of tuberculosis (TB) — an illness that kills more people than any other infectious disease — rose in the U.S. during 2022, per the Centers for Disease Control and Prevention (CDC). And some ...

A clinical trial published in the New England Journal of Medicine showed that the oral antibiotic levofloxacin taken once-daily for six months substantially reduced the risk of developing ...

Tuberculosis (TB), one of the leading infectious disease killers worldwide, has long posed a challenge, particularly with the rise of drug-resistant forms. However, new research offers fresh hope in ...

Only four out of 10 patients with extensively drug-resistant tuberculosis (TB) in Europe achieved successful treatment outcomes, a rate markedly lower than that for other forms of drug-resistant TB ...

First-ever clinical trial exclusively conducted among people with hard-to-treat form of tuberculosis known as pre-extensively drug-resistant TB shows many patients benefit from shorter, simpler ...

A patient we'll call Juliet is a young woman you wouldn't have noticed if you had happened upon her in the market or on a bus in the African country where she lived. She looks healthy. But she isn’t.